TriangleHEALTH PROFESSIONAL · SOURCE READING
Mosunetuzumab
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Mosunetuzumab is a bispecific T-cell engager that binds to CD20 and CD3.[25]
Source links and citations
Evidence (mosunetuzumab):
A single-arm, multicenter, phase II study included 90 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy (including an anti-CD20 therapy and an alkylating agent). Patients received mosunetuzumab.[27]
Source links and citations
A single-arm, multicenter, phase II study included 90 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy (including an anti-CD20 therapy and an alkylating agent). Patients received mosunetuzumab.[27]
With a median follow-up of 37.4 months, the objective response rate was 77.8% (95% CI, 67.8%–85.9%), and the complete response rate was 60.0% (95% CI, 49.1%–70.2%), per investigator assessment. The median PFS (per investigator assessment) was 24.0 months. The 3-year OS rate was 82.4% (95% CI, 73.8%–91.0%).[27][Level of evidence C1]
Source links and citations
A single-arm, multicenter, phase II study included 90 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy (including an anti-CD20 therapy and an alkylating agent). Patients received mosunetuzumab.[27]
Cytokine release syndrome occurred in 44.4% of patients; 97.2% of cases were grade 1 or 2 in severity.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice